1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?

BACKGROUND: Novel therapies for multidrug-resistant TB are needed and new BLIs could answer this call. Mtb encodes for BlaC, a class A β-lactamase. BlaC is inhibited by clavulanate (CLA) while the DBO avibactam (AVI) is an inefficient inhibitor (low k(2)/K value). Carbapenems are hydrolyzed slowly b...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, David, Bethel, Christopher, Taracilla, Magdalena A, Li, Qing, Dousa, Khalid M, Kurz, Sebastian G, Nguyen, Liem, Kreiswirth, Barry N, Boom, Wilem, Bonomo, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643912/
http://dx.doi.org/10.1093/ofid/ofab466.1582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643912/
http://dx.doi.org/10.1093/ofid/ofab466.1582

Ejemplares similares